Myriad Genetics (MYGN) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MYGN Myriad Genetics

Watchlist

14.510
-0.830-5.41%

Close Dec 11 16:00 ET

12.010
-2.500-17.23%

Pre 04:59 ET

1.32BMarket Cap-11.34P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top Premarket Decliners
MT Newswires21minutes ago
Express News | Myriad Genetics Inc : Jefferies Cuts Target Price to $13 From $15
Reuters01:47 ET
Reported Earlier, Myriad Genetics Engages Unitedhealthcare On Pharmacogenetic Testing Policy, Seeks Continued Access To Genesight In 2025
BenzingaDec 11 02:35 ET
Myriad Genetics Talks With UnitedHealthcare on Insurance Exclusion Might Extend Into 2025
WSJDec 10 19:01 ET
Myriad Genetics: During 3Q Earnings Call Provided Estimate of 2024 Fincl Impact of UNH's Updated Medical Policy, Myriad Reaffirms Estimate >MYGN
Dow JonesDec 10 18:37 ET
Myriad Genetics: Desire Resolution Ahead of Yr-End, But Discussions May Extend Into Early 2025 >MYGN
Dow JonesDec 10 18:37 ET

Comments

905745367

Dec 6 09:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 20 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Heat List

Overall

No Data